Zhengye Biotechnology Holding ZYBT
NASDAQ ZYBT
$1.52 -0.02 (-1.30%)
At close: Nov 11, 2026 · 4:00 PM EST

Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2023 - 2025)

Updated

Zhengye Biotechnology Holding's Accumulated Expenses came in at $488,257 for the quarter ended Dec 31, 2025, down 37.6% from $781,975 a year earlier.

Analysis

Zhengye Biotechnology Holding (ZYBT) Accumulated Expenses (2023 - 2025) Analysis & Trends

As of Dec 31, 2025, Zhengye Biotechnology Holding's Accumulated Expenses was $495,000, down 35.6% from the prior year.

  • Going back by year, Accumulated Expenses was $769,000 in the year ended Dec 31, 2024 (+88.6%) and $407,810 in the year ended Dec 31, 2023.
  • The figure for the quarter ended Dec 31, 2025 represents the lowest quarterly Accumulated Expenses since the quarter ended Dec 31, 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Zhengye Biotechnology Holding 72.98 Mn 69.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 494,990.07
Jun 30, 2025 529,000.00
Dec 31, 2024 352,283.46
Dec 31, 2023 405,515.69
API Access

Zhengye Biotechnology Holding Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=accumulated-expenses&ticker=ZYBT&period=max&api_key=YOUR_API_KEY